Analysts expect Arcadia Biosciences, Inc. to report revenue of 2.51 M for Q3 26, against a range of 2.38 M to 2.63 M. The most recent reported quarter, Q2 26, came in at 1.44 M, a 19.9% miss against the 1.80 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.54 M | 1.22 M | 1.20 M | 1.46 M | 1.30 M | 901,000.00 | 1.10 M | 1.44 M | - | - | - | - | - | - |
| High Estimate | 1.47 M | 1.18 M | 1.43 M | 1.55 M | 1.95 M | 1.39 M | 1.65 M | 1.91 M | 2.63 M | 1.80 M | 1.51 M | 1.69 M | 2.88 M | 2.40 M |
| Low Estimate | 1.21 M | 1.03 M | 1.34 M | 1.44 M | 1.75 M | 1.25 M | 1.35 M | 1.68 M | 2.38 M | 1.68 M | 1.40 M | 1.50 M | 2.37 M | 1.96 M |
| Consensus Estimate | 1.34 M | 1.11 M | 1.38 M | 1.50 M | 1.85 M | 1.32 M | 1.50 M | 1.80 M | 2.51 M | 1.74 M | 1.45 M | 1.60 M | 2.62 M | 2.18 M |
Analysts expect Arcadia Biosciences, Inc. to report earnings per share of -0.44 for Q3 26, against a range of -0.47 to -0.41. The most recent reported quarter, Q2 26, came in at -2.09, a 294.3% miss against the -0.53 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.18 | -2.98 | 1.90 | -3.26 | -0.85 | -0.97 | -2.11 | -2.09 | - | - | - | - | - | - |
| High Estimate | -0.81 | -0.83 | -0.99 | -0.72 | -0.48 | -0.59 | -0.70 | -0.48 | -0.41 | -0.58 | -3.18 | -2.78 | -0.39 | -0.08 |
| Low Estimate | -0.93 | -1.01 | -1.07 | -0.80 | -0.58 | -0.67 | -0.80 | -0.58 | -0.47 | -0.70 | -3.44 | -3.26 | -0.43 | -0.08 |
| Consensus Estimate | -0.87 | -0.92 | -1.03 | -0.76 | -0.53 | -0.63 | -0.75 | -0.53 | -0.44 | -0.64 | -3.31 | -3.02 | -0.41 | -0.08 |